Haleon plc (HLN) KPIs and segments
Close on Nov 18, 2026Market cap $40.64BP/E 18.6Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Haleon · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Haleon: 38 chỉ số vận hành, trong đó có Group Organic Revenue Growth, North America — Organic Revenue Growth và Europe — Organic Revenue Growth, lấy từ 64 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Group Organic Revenue Growth (%)5 | 2.60 | 3.10 | 2.20 | 2.10 | 3.40 | 3.00 | 3.50 | 6.80 | 6.10 | 4.10 | 3.00 | ||
Group Organic Price Growth (%) | 2.10 | 1.70 | 2.40 | 2.40 | 1.80 | 2.50 | 2.40 | 2.70 | 3.30 | 3.40 | 5.00 | ||
Group Organic Volume / Mix Growth (%) | 0.50 | 1.40 | -0.20 | -0.30 | 1.60 | 0.50 | 1.10 | 4.10 | 2.80 | 0.70 | -2.00 | ||
Group Reported Revenue Growth (%) | 2.50 | 4.50 | 0.10 | -0.30 | 0.70 | -5.30 | -2.30 | ||||||
Revenue Bridge — Exchange Rate Effect (Reported to Organic Reconciliation, %) | 0.00 | -1.50 | 2.10 | 2.40 | 0.40 | 5.50 | 2.90 | ||||||
Revenue Bridge — Organic Adjustments (M&A and Manufacturing Service Agreements, %) | 0.10 | 0.10 | 0.00 | 0.00 | 2.30 | 2.80 | 2.90 | ||||||
North America — Organic Revenue Growth (%)3 | 2.50 | 3.10 | 1.00 | -1.00 | 0.40 | -1.80 | 1.00 | ||||||
North America — Organic Price Growth (%) | 1.80 | 1.10 | 3.70 | 2.70 | 0.70 | 1.20 | -0.80 | ||||||
North America — Organic Volume / Mix Growth (%) | 0.70 | 2.00 | -2.70 | -3.70 | -0.30 | -3.00 | 1.80 | ||||||
North America — Reported Revenue Growth (%) | 1.50 | 3.10 | -4.90 | -4.70 | -2.00 | -9.30 | -1.60 | ||||||
Europe — Organic Revenue Growth (%)3 | -0.60 | 0.40 | 0.80 | 1.70 | 3.80 | 4.10 | 4.50 | ||||||
Europe — Organic Price Growth (%) | 2.10 | 2.20 | 2.20 | 3.20 | 2.60 | ||||||||
Europe — Organic Volume / Mix Growth (%) | -2.70 | -1.80 | -1.40 | 0.60 | 1.50 | ||||||||
Europe — Reported Revenue Growth (%) | -0.90 | 3.30 | 6.30 | 8.50 | 1.90 | -1.30 | -3.50 | ||||||
Asia Pacific (New Structure) — Organic Revenue Growth (%)3 | 3.90 | 4.00 | 2.70 | 4.50 | 3.40 | 5.30 | 3.50 | ||||||
Asia Pacific (New Structure) — Organic Price Growth (%) | -0.30 | -1.40 | 0.20 | 0.20 | 1.60 | ||||||||
Asia Pacific (New Structure) — Organic Volume / Mix Growth (%) | 4.20 | 5.40 | 2.50 | 3.20 | 3.70 | ||||||||
Asia Pacific (New Structure) — Reported Revenue Growth (%) | 5.30 | 6.00 | 0.00 | 2.00 | -1.40 | -1.10 | -0.30 | ||||||
International (Latin America, Middle East & Africa, India) — Organic Revenue Growth (%)3 | 6.90 | 6.40 | 6.30 | 7.20 | 10.20 | 8.00 | 6.70 | ||||||
International — Organic Price Growth (%) | 5.60 | 5.80 | 3.00 | 4.30 | 5.70 | ||||||||
International — Organic Volume / Mix Growth (%) | 1.30 | 0.60 | 3.30 | 5.90 | 2.30 | ||||||||
International — Reported Revenue Growth (%) | 6.80 | 7.40 | 0.40 | -4.90 | 7.60 | -8.80 | -3.80 | ||||||
Emerging Markets — Organic Revenue Growth (%) | 5.10 | 6.30 | 4.30 | 7.10 | 6.50 | ||||||||
Oral Health (Sensodyne, parodontax, Polident/Poligrip, Aquafresh) — Reported Revenue (£m)3 | 930.00 | 906.00 | 932.00 | 866.00 | 867.00 | 848.00 | 880.00 | 810.00 | |||||
Oral Health — Organic Revenue Growth (%) | 8.80 | 6.20 | 8.30 | 9.30 | 6.90 | 8.70 | 6.60 | 10.60 | 8.20 | 9.10 | 10.60 | ||
Oral Health — Reported Revenue Growth (%) | 7.30 | 6.80 | 5.90 | 7.00 | 2.30 | 3.00 | |||||||
Oral Health — Exchange Rate Effect (Reconciliation, %) | 1.50 | -0.60 | 2.40 | -0.10 | 6.40 | 3.60 | |||||||
Pain Relief (Panadol, Advil, Voltaren, Fenbid) — Reported Revenue (£m)3 | 657.00 | 669.00 | 654.00 | 631.00 | 647.00 | 625.00 | 661.00 | 628.00 | |||||
Pain Relief — Organic Revenue Growth (%) | 0.50 | 4.60 | -0.30 | 0.50 | 3.70 | 2.50 | 2.60 | 7.40 | 3.10 | -4.00 | -4.80 | ||
Pain Relief — Reported Revenue Growth (%) | 1.50 | 7.00 | -1.10 | 3.00 | -2.50 | -0.20 | |||||||
Pain Relief — Exchange Rate Effect (Reconciliation, %) | -1.00 | -2.40 | 0.80 | 0.70 | 5.00 | 2.80 | |||||||
Vitamins, Minerals and Supplements — VMS (Centrum, Caltrate, Emergen-C) — Reported Revenue (£m)3 | 423.00 | 435.00 | 414.00 | 430.00 | 422.00 | 417.00 | 416.00 | 407.00 | |||||
Vitamins, Minerals and Supplements — VMS — Organic Revenue Growth (%) | -0.50 | 2.20 | 1.70 | 1.20 | 4.90 | 0.90 | 0.90 | 8.20 | 3.70 | 8.50 | 9.90 | ||
Vitamins, Minerals and Supplements — VMS — Reported Revenue Growth (%) | 0.20 | 4.30 | -0.50 | 3.70 | -4.10 | -1.40 | |||||||
Vitamins, Minerals and Supplements — VMS — Exchange Rate Effect (Reconciliation, %) | -0.70 | -2.10 | 2.20 | 1.20 | 5.00 | 2.30 | |||||||
Respiratory Health (Otrivin, Theraflu, Flonase, Robitussin, Contac, Nicotinell) — Reported Revenue (£m)3 | 499.00 | 351.00 | 499.00 | 470.00 | 510.00 | 368.00 | 525.00 | 581.00 | |||||
Respiratory Health — Organic Revenue Growth (%) | -2.00 | -6.50 | -3.40 | -4.60 | -1.80 | -2.00 | 0.70 | -2.60 | 8.20 | 1.30 | -2.70 | ||
Respiratory Health — Reported Revenue Growth (%) | -2.20 | -4.60 | -5.00 | -12.20 | -18.90 | -11.00 | |||||||
Respiratory Health — Exchange Rate Effect (Reconciliation, %) | 0.20 | -1.90 | 1.60 | 0.20 | 4.00 | 2.20 | |||||||
Digestive Health (Tums, ENO, Nexium, Benefiber) — Reported Revenue (£m)3 | 245.00 | 251.00 | 239.00 | 256.00 | 240.00 | 237.00 | 254.00 | 239.00 | |||||
Digestive Health — Organic Revenue Growth (%) | 2.50 | 5.50 | -0.40 | 0.70 | 2.10 | -2.80 | 2.30 | 5.80 | 9.00 | 5.20 | 2.20 | ||
Digestive Health — Reported Revenue Growth (%) | 2.10 | 5.90 | -5.90 | 0.40 | -10.20 | -0.80 | |||||||
Digestive Health — Exchange Rate Effect (Reconciliation, %) | 0.40 | -0.40 | 5.50 | 1.70 | 7.20 | 2.40 | |||||||
Therapeutic Skin Health and Other (Bactroban, Fenistil, Abreva, Zovirax) — Reported Revenue (£m)3 | 114.00 | 133.00 | 119.00 | 98.00 | 113.00 | 132.00 | 117.00 | 115.00 | |||||
Therapeutic Skin Health and Other — Organic Revenue Growth (%) | -0.70 | 0.40 | 3.00 | -4.30 | -1.10 | 2.50 | 10.40 | 24.20 | 0.70 | 10.70 | 7.40 | ||
Therapeutic Skin Health and Other — Reported Revenue Growth (%) | 0.90 | 0.80 | 1.70 | -1.70 | -13.20 | -13.30 | |||||||
Therapeutic Skin Health and Other — Exchange Rate Effect (Reconciliation, %) | -3.60 | -2.30 | 0.90 | -1.70 | 5.30 | 4.40 | |||||||
Group Total — Reported Revenue (£m)4 | 2,868.00 | 2,745.00 | 2,857.00 | 2,751.00 | 2,799.00 | 2,627.00 | 2,853.00 | 2,780.00 | 2,775.00 | 2,919.00 | 2,798.00 | ||
North America — Reported Revenue (£m) | 992.00 | 898.00 | 932.00 | 1,038.00 | 977.00 | 871.00 | 980.00 | ||||||
Europe — Reported Revenue (£m) | 798.00 | 781.00 | 850.00 | 724.00 | 805.00 | 756.00 | 800.00 | ||||||
Asia Pacific (New Structure) — Reported Revenue (£m) | 593.00 | 585.00 | 597.00 | 522.00 | 563.00 | 552.00 | 597.00 | ||||||
International — Reported Revenue (£m) | 485.00 | 481.00 | 478.00 | 467.00 | 454.00 | 448.00 | 476.00 | ||||||
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Haleon plc (CIK 0001900304, LSE / NYSE: HLN) reports under IFRS in Pounds Sterling (GBP, £m) with a calendar fiscal year ending December 31. Latest reported quarter is Q3 2026 (three months ended September 30, 2026; Form 6-K filed October 29, 2026); latest monthly share capital and FX period is October 2026.
- Core operational growth KPIs track Organic Revenue Growth (%) decomposed into Organic Price (%) and Organic Volume/Mix (%), alongside the full Reported-to-Organic Revenue Bridge (Exchange Rate Effect % and Organic Adjustments / Net M&A %) across the Group, the 4 Operating Units established in January 2026 (North America, Europe, Asia Pacific, International, with restated comparatives from FY2024 and Q1 2025), Emerging Markets, and all 6 global Product Categories (Oral Health, Pain Relief, Vitamins, Minerals & Supplements, Respiratory Health, Digestive Health, and Therapeutic Skin Health & Other).
- Monthly operational series include 20 consecutive monthly Form 6-K Total Voting Rights and Capital notifications (March 2025–October 2026, plus earlier filings back to January 2024) tracking issued ordinary shares, treasury shares, and total voting rights as share buybacks are executed, alongside monthly U.S. Bureau of Labor Statistics (BLS) CPI/PPI benchmarks for OTC Drugs, Dental/Personal Care Products, and Pharmaceutical Manufacturing and Federal Reserve (FRED) FX rates.
- Supply chain and sustainability disclosures from the 2022–2025 ESG Databooks provide physical manufacturing tonnage of raw materials and packaging (paper, plastic, glass, metal) across both Haleon-controlled factories and third-party contract manufacturers, sustainably sourced palm oil tonnage, workforce headcount, remuneration, Speak Up ethics investigations, safety rates, energy consumption, Scope 1/2/3 GHG emissions, and water withdrawal.
- Haleon plc's standalone parent company balance sheet in the Annual Report (prepared under FRS 102) represents a non-operating holding company with no standalone product revenue statement; therefore, Consolidated minus Standalone subtraction is not applicable. All figures are strictly as published in official filings, except Q2 2025 product category revenue split as H1 2025 minus Q1 2025 (marked with exact formula).
Không hiện vì thiếu các kỳ gần đây (5)
- Power Brands Organic Revenue Growth (%) — Reported from FY2022 (+10.1%), FY2023 (+9.1%), and FY2024 (+6.3%) through Q3 2024 (+5.4%), then discontinued by Haleon from FY2025 onwards.
- E-Commerce Share of Total Sales (%) & Growth (%) — Disclosed intermittently in FY2022 (9% of sales) and FY2023 (10% of sales, +17% growth), not reported as a continuous quarterly or annual series in 2024–2026.
- Legacy 3-Region Quarterly Revenue & Organic Growth (EMEA & LatAm, Asia Pacific incl. India) — Quarterly reporting ended in Q2 2026 upon full transition to the 4-Segment Operating Unit structure (North America, Europe, Asia Pacific, International) in Q3 2026; annual series (FY2021–FY2025) are retained.
- Legacy Combined Category 'Digestive Health and Other' Revenue (£m) — Superseded in May 2025 when Haleon split the category into standalone 'Digestive Health' and 'Therapeutic Skin Health and Other' and moved Smokers' Health into 'Respiratory Health' (with restated comparative figures from FY2023).
- Health Inclusivity People Empowered (millions) — Reported as lower-bound figures ('22 million+' in 2022, '41 million+' in 2023, '50 million+' in 2024, '74 million+' in 2025) rather than exact point values.
Dữ liệu cập nhật 2026-11-10.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Organic Revenue Growth Decomposition (Price × Volume/Mix & Revenue Bridge)
- Group Organic Revenue Growth (%)11 kỳ
- North America — Organic Revenue Growth (%)7 kỳ
- Europe — Organic Revenue Growth (%)7 kỳ
- Asia Pacific (New Structure) — Organic Revenue Growth (%)7 kỳ
- International (Latin America, Middle East & Africa, India) — Organic Revenue Growth (%)7 kỳ
- Emerging Markets — Organic Revenue Growth (%)5 kỳ
- EMEA & LatAm (Legacy 3-Region Structure, FY2021–FY2025) — Organic Revenue Growth (%)5 kỳ
- Asia Pacific (Legacy 3-Region Structure incl. India, FY2021–FY2025) — Organic Revenue Growth (%)5 kỳ
Product Category Revenue & Organic Growth Bridge (6 Categories)
- Oral Health (Sensodyne, parodontax, Polident/Poligrip, Aquafresh) — Reported Revenue (£m)8 kỳ
- Pain Relief (Panadol, Advil, Voltaren, Fenbid) — Reported Revenue (£m)8 kỳ
- Vitamins, Minerals and Supplements — VMS (Centrum, Caltrate, Emergen-C) — Reported Revenue (£m)8 kỳ
- Respiratory Health (Otrivin, Theraflu, Flonase, Robitussin, Contac, Nicotinell) — Reported Revenue (£m)8 kỳ
- Digestive Health (Tums, ENO, Nexium, Benefiber) — Reported Revenue (£m)8 kỳ
- Therapeutic Skin Health and Other (Bactroban, Fenistil, Abreva, Zovirax) — Reported Revenue (£m)8 kỳ
Geographic Segment Revenue & Adjusted Operating Profitability
Market Share, Commercial Investment (A&P), Cash Conversion & Deleveraging KPIs
Monthly Share Capital & Voting Rights, Country Revenue & Subsidiary Ownership
Manufacturing Footprint, Physical Raw/Packaging Tonnage, Workforce & Sustainability
- In-House Dedicated Consumer Health Manufacturing Sites (count)4 kỳ
- Total Materials & Packaging Used to Manufacture Products — Operational Control & 3P Combined (thousand tonnes)4 kỳ
- Total Materials & Packaging Used at Sites Under Haleon Operational Control (thousand tonnes)4 kỳ
- Recycle-Ready Product Packaging Share (%)4 kỳ
- Total Year-End Employees (headcount)4 kỳ
- Speak Up & Ethics Channels — New Cases Raised and Logged (count)3 kỳ
- Total Operational Energy Consumed (GWh)4 kỳ
External Consumer Health Industry Benchmarks — U.S. OTC Drug & Dental CPI, Pharma PPI & FX (Monthly)
IFRS Financial Statements & Accounting Segments (Database Reference)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Haleon
- Haleon Q3 2026 Trading Statement (Form 6-K Ex. 99.1, filed Oct 29, 2026) ↗
- Haleon 2025 Annual Report and Form 20-F (Form 6-K Ex. 99.1, filed Mar 16, 2026) ↗
- Haleon H1 2026 Half Year Results Presentation Slides ↗
- Haleon 2025 ESG Databook (Issued March 2026) ↗
- Haleon 2025 Full Year Results Announcement (Form 6-K Ex. 99.1, filed Feb 25, 2026) ↗
- Haleon Form 20-F (filed 2026-03-13, SEC EDGAR accession 0001104659-26-027443) ↗
- Haleon FY 2025 Full Year Results Presentation Slides ↗
- Haleon 2024 Full Year Results Announcement (Form 6-K Ex. 99.1, filed Feb 27, 2025) ↗
- Haleon Form 6-K Total Voting Rights and Capital (2026-10, Accession 0001654954-26-009333) ↗
- U.S. Bureau of Labor Statistics (BLS Series CUUR0000SEMF02) ↗
- Federal Reserve Economic Data (FRED Series DEXUSUK — H.10 Foreign Exchange Rates) ↗
See a number that looks wrong?